Global BRCA Tests (In Vitro Diagnostics) Market Analysis and Forecast Model, with COVID-19 Market Impacts, 2015-2020 & 2020-2030 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "BRCA Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact)" report has been added to ResearchAndMarkets.com's offering.

BRCA Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on BRCA Tests market for the year 2020 and beyond. Globally, ovarian cancer is the 8th most common cause of cancer death in women, with the World Health Organization estimating that 295,414 new cases were reported in 2018. The highest rates of ovarian cancer occur in Russia and Eastern Europe, whereas countries such as Brazil, China, India, and Saudi Arabia have significantly lower rates.

Breast cancer is the most frequent cancer in women and is now the leading cause of female cancer-related deaths worldwide. Breast cancer in men is rare. Triple-negative breast cancer (TNBC) refers to breast cancer patients that do not express ER, PgR, and HER2. Approximately 10-20% of breast cancer cases are triple-negative and these patients have poorer outcomes compared to individuals with other breast cancer subtypes. This is attributed to the more aggressive nature of TNBC tumors and the absence of targeted molecular therapies

BRCA1 and BRCA2 are DNA repair proteins required for proper maintenance of the genome. There are over 1000 known mutations in BRCA1/2 including individual nucleotide changes, small insertions or deletions (indels), and large genomic rearrangements (LGRs).

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Companies Mentioned

• Agilent Technologies Inc
• Illumina Inc
• Thermo Fisher Scientific Inc
• Sysmex Corp
• Qiagen NV
• Takara Bio Inc
• New England Biolabs Inc
• EntroGen, Inc

Key Inclusions of the market model are:

Currently marketed BRCA Tests and evolving competitive landscape

• Insightful review of the key industry trends.
• Annualized total BRCA Tests market revenue by segment and market outlooks from 2015-2030.
• Granular data on total procedures, units, average selling prices and market values by segment.

Global, Regional and Country level market specific insights

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, analysts provide unique country specific insights on the market.
• SWOT analysis for BRCA Tests market.
• Competitive dynamics insights and trends provided for BRCA Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the BRCA Tests market place to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

• Understand the impact of COVID-19 on BRCA Tests market.
• Develop and design you're in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving BRCA Tests market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the BRCA Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track device sales in the global and country-specific BRCA Tests market from 2015-2030.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

For more information about this report visit https://www.researchandmarkets.com/r/ges034